Human Anti-IL13 Recombinant Antibody (clone V2.11) (CAT#: HPAB-1742-FY)

Figure 1 A graph depicts the neutralization of NHP IL-13 activity by humanized MJ2-7 v.211.

Figure 2 A graph depicts the neutralization of NHP IL-13 activity by humanized MJ2-7 v.211.

Figure 3 A graph depicts the binding of varying concentrations (0.09-600 nM) of NHP IL-13 to captured hMJ2-7 v.2-11 antibody.

Figure 4 Show total of BAL cells/ml in BAL fluids in control and antibody-treated cynomolgus monkeys pre- and post-Ascaris challenge.

Figure 5 Depicts a decrease in eotaxin levels in concentrated BAL fluids from cynomolgus monkeys treated with mAb 13.2-(gray circles) or MJ2-7-(gray triangles) antibodies compared to a control (dark circles).

Figure 6 Shows the concentrations of [125I]-labeled humanized 13.2v.2 anti-IL-13 antibody and [251I]-labeled humanized MJ2-7v.2-11 antibody in various mouse and rat tissue, respectively.

Figure 7 Showing observed and predicted IL-13 and anti-IL-13 antibody levels over time.

1 mg/kg of humanized MJ2-7v.2-11 antibody was administered to naïve cynomolgus monkeys. Total IL-13 and humanized MJ2-7v.2-11 serum levels were quantified over a period of 0-45 days using a specific ELISA.

Figure 8 Showing observed and predicted IL-13 and anti-IL-13 antibody levels over time.

1 mg/kg of humanized MJ2-7v.2-11 antibody was administered to naïve cynomolgus monkeys. Total IL-13 and humanized MJ2-7v.2-11 serum levels were quantified over a period of 0-45 days using a specific ELISA.